Tau passive immunization inhibits not only tau but also Aβ pathology

Chaperone-like Antibodies Targeting Misfolded Tau Protein: New Vistas in the Immunotherapy of Neurodegenerative Foldopathies

(2017) Norbert Zilka et al.   JOURNAL OF ALZHEIMERS DISEASE

Hyperphosphorylation determines both the spread and the morphology of tau pathology

(2016) Wen Hu et al.   Alzheimers & Dementia

Internalization of tau antibody and pathological tau protein detected with a flow cytometry multiplexing approach

(2016) Dov B. Shamir et al.   Alzheimers & Dementia

Two Phase 2 Multiple Ascending–Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer’s Disease

(2016) Florence Pasquier et al.   JOURNAL OF ALZHEIMERS DISEASE

Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

(2016) Rik Vandenberghe et al.   Alzheimers Research & Therapy

2015 Alzheimer's disease facts and figures

(2015)   Alzheimers & Dementia

Early investigational drugs targeting tau protein for the treatment of Alzheimer’s disease

(2015) Keshav Anand et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Human secreted tau increases amyloid-beta production

(2015) Jessica Bright et al.   NEUROBIOLOGY OF AGING

Tau Immunotherapy

(2015) Einar M. Sigurdsson   Neurodegenerative Diseases

Tau immunotherapy for Alzheimer's disease

(2015) Jan Torleif Pedersen et al.   TRENDS IN MOLECULAR MEDICINE

Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy Models

(2015) Sethu Sankaranarayanan et al.   PLoS One

Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer‘s disease

(2014) Ludovic Collin et al.   BRAIN

Intracellular Antibody Immunity

(2014) Ruth E. Watkinson et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies

(2014) Chun-ling Dai et al.   JOURNAL OF NEURAL TRANSMISSION

Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease

(2014) Syed Faraz Kazim et al.   NEUROBIOLOGY OF DISEASE

Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies

(2014) David W. Sanders et al.   NEURON

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid

(2013) Heiko Braak et al.   ACTA NEUROPATHOLOGICA

Physiological release of endogenous tau is stimulated by neuronal activity

(2013) Amy M Pooler et al.   EMBO REPORTS

Spreading of tau pathology in Alzheimer's disease by cell-to-cell transmission

(2013) Nguyen-Vi Mohamed et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Antibody Uptake into Neurons Occurs Primarily via Clathrin-dependent Fcγ Receptor Endocytosis and Is a Prerequisite for Acute Tau Protein Clearance

(2013) Erin E. Congdon et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Two Novel Tau Antibodies Targeting the 396/404 Region Are Primarily Taken Up by Neurons and Reduce Tau Protein Pathology

(2013) Jiaping Gu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

(2013) Clifford R Jack et al.   LANCET NEUROLOGY

Tau immunotherapy targets transcellular propagation

(2013) Monica Hoyos Flight   NATURE REVIEWS DRUG DISCOVERY

Alzheimer disease therapy—moving from amyloid-β to tau

(2013) Ezio Giacobini et al.   Nature Reviews Neurology

Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo

(2013) Kiran Yanamandra et al.   NEURON

Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy

(2013) Clara Theunis et al.   PLoS One

Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease

(2013) Jere E. Meredith Jr. et al.   PLoS One

Brain homogenates from human tauopathies induce tau inclusions in mouse brain

(2013) Florence Clavaguera et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Changes in Amyloid-  and Tau in the Cerebrospinal Fluid of Transgenic Mice Overexpressing Amyloid Precursor Protein

(2013) L. F. Maia et al.   Science Translational Medicine

What does complement do in Alzheimer’s disease? Old molecules with new insights

(2013) Yong Shen et al.   Translational Neurodegeneration

Targeting Phospho-Ser422 by Active Tau Immunotherapy in the THYTau22 Mouse Model: A Suitable Therapeutic Approach

(2012) Nadege Zommer et al.   Current Alzheimer Research

Processing Body and Stress Granule Assembly Occur by Independent and Differentially Regulated Pathways in Saccharomyces cerevisiae

(2012) K. H. Shah et al.   GENETICS

Complement component C3 and complement receptor type 3 contribute to the phagocytosis and clearance of fibrillar Aβ by microglia

(2012) Hongjun Fu et al.   GLIA

Lithium rescues synaptic plasticity and memory in Down syndrome mice

(2012) Andrea Contestabile et al.   JOURNAL OF CLINICAL INVESTIGATION

Constitutive secretion of tau protein by an unconventional mechanism

(2012) Xiyun Chai et al.   NEUROBIOLOGY OF DISEASE

Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models

(2011) Xiyun Chai et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

(2011) Allal Boutajangout et al.   JOURNAL OF NEUROCHEMISTRY

Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer's disease

(2011) Maria I Fonseca et al.   Journal of Neuroinflammation

Tau-Targeted Immunization Impedes Progression of Neurofibrillary Histopathology in Aged P301L Tau Transgenic Mice

(2011) Mian Bi et al.   PLoS One

Mechanistic Studies of Antibody-Mediated Clearance of Tau Aggregates Using an ex vivo Brain Slice Model

(2011) Pavan K. Krishnamurthy et al.   Frontiers in Psychiatry

Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting Aβ and tau pathologies in 3xTg-AD mice

(2010) Julie Blanchard et al.   ACTA NEUROPATHOLOGICA

Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice

(2010) Moran Boimel et al.   EXPERIMENTAL NEUROLOGY

Complement receptor 3 (CD11b/CD18) is implicated in the elimination of β-amyloid peptides

(2010) Nada Choucair-Jaafar et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Object location memory in mice: Pharmacological validation and further evidence of hippocampal CA1 participation

(2009) Fabrício Luiz Assini et al.   BEHAVIOURAL BRAIN RESEARCH

Propagation of Tau Misfolding from the Outside to the Inside of a Cell

(2009) Bess Frost et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Transmission and spreading of tauopathy in transgenic mouse brain

(2009) Florence Clavaguera et al.   NATURE CELL BIOLOGY

Complement C3 Deficiency Leads to Accelerated Amyloid   Plaque Deposition and Neurodegeneration and Modulation of the Microglia/Macrophage Phenotype in Amyloid Precursor Protein Transgenic Mice

(2008) M. Maier et al.   JOURNAL OF NEUROSCIENCE